Acceleron Pharma Inc. (NASDAQ:XLRN)’s share price traded up 3.9% during mid-day trading on Wednesday . The company traded as high as $34.49 and last traded at $34.03, with a volume of 199,905 shares traded. The stock had previously closed at $32.76.

A number of equities analysts recently issued reports on the stock. Barclays PLC assumed coverage on shares of Acceleron Pharma in a research report on Wednesday, April 27th. They set an “overweight” rating and a $40.00 price objective for the company. Piper Jaffray Cos. reiterated a “buy” rating on shares of Acceleron Pharma in a research report on Friday, June 10th. Zacks Investment Research upgraded shares of Acceleron Pharma from a “strong sell” rating to a “hold” rating and set a $35.00 price objective for the company in a research report on Saturday, May 7th. Morgan Stanley reiterated an “overweight” rating on shares of Acceleron Pharma in a research report on Wednesday, June 29th. Finally, FBR & Co reiterated a “buy” rating and set a $63.00 price objective on shares of Acceleron Pharma in a research report on Monday, June 13th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $48.14.

The firm has a 50 day moving average of $34.66 and a 200-day moving average of $31.96. The stock’s market capitalization is $1.25 billion.

Acceleron Pharma (NASDAQ:XLRN) last released its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.40. The firm earned $18.20 million during the quarter, compared to the consensus estimate of $8.70 million. During the same quarter last year, the business posted ($0.45) earnings per share. Acceleron Pharma’s revenue was up 311.8% compared to the same quarter last year. On average, equities analysts anticipate that Acceleron Pharma Inc. will post ($1.56) EPS for the current year.

In other Acceleron Pharma news, EVP Matthew L. Sherman sold 26,000 shares of Acceleron Pharma stock in a transaction that occurred on Friday, July 1st. The shares were sold at an average price of $34.74, for a total transaction of $903,240.00. Following the completion of the sale, the executive vice president now directly owns 91,500 shares in the company, valued at $3,178,710. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO John L. Knopf sold 28,022 shares of Acceleron Pharma stock in a transaction that occurred on Friday, July 1st. The shares were sold at an average price of $34.72, for a total transaction of $972,923.84. Following the sale, the chief executive officer now owns 147,106 shares of the company’s stock, valued at $5,107,520.32. The disclosure for this sale can be found here.

A number of large investors recently made changes to their positions in the stock. Brown Advisory Inc. raised its stake in shares of Acceleron Pharma by 6.1% in the fourth quarter. Brown Advisory Inc. now owns 283,353 shares of the biopharmaceutical company’s stock valued at $13,817,000 after buying an additional 16,370 shares during the last quarter. TD Asset Management Inc. raised its stake in shares of Acceleron Pharma by 0.8% in the fourth quarter. TD Asset Management Inc. now owns 63,100 shares of the biopharmaceutical company’s stock valued at $3,077,000 after buying an additional 500 shares during the last quarter. Mutual of America Capital Management LLC raised its stake in shares of Acceleron Pharma by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 44,363 shares of the biopharmaceutical company’s stock valued at $2,163,000 after buying an additional 260 shares during the last quarter. California State Teachers Retirement System raised its stake in shares of Acceleron Pharma by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 40,191 shares of the biopharmaceutical company’s stock valued at $1,960,000 after buying an additional 642 shares during the last quarter. Finally, ProShare Advisors LLC raised its stake in shares of Acceleron Pharma by 9.6% in the fourth quarter. ProShare Advisors LLC now owns 29,906 shares of the biopharmaceutical company’s stock valued at $1,458,000 after buying an additional 2,619 shares during the last quarter.

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic candidates that are based on the mechanisms that the human body uses to regulate the growth and repair of its cells and tissues. Its segment operates through discovery, development and commercialization of protein therapeutics for cancer and rare diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.